Zoetis (ZTS) Non-Current Assets (2012 - 2026)
Zoetis' (ZTS) quarterly Non-Current Assets came in at $8.7 billion in Q1 2026, up 5.58% year-on-year from $8.2 billion in Q1 2025, and little changed on a QoQ basis from $8.7 billion in Q4 2025.
Zoetis (ZTS) Non-Current Assets (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Non-Current Assets data on file, last reported at $8.7 billion in Q1 2026.
- On a quarterly basis, Non-Current Assets rose 5.58% year-over-year to $8.7 billion in Q1 2026; TTM through Mar 2026 was $34.5 billion, a 6.33% increase from a year earlier, with the FY2025 full-year figure at $8.7 billion, up 6.12% from the prior year.
- Non-Current Assets for Q1 2026 stood at $8.7 billion, roughly flat from $8.7 billion in the prior quarter.
- Over the last five years, Non-Current Assets for ZTS reached as high as $8.7 billion in Q4 2025 and fell as low as $7.0 billion in Q1 2022.
- Historically, Non-Current Assets has averaged $7.9 billion across 5 years, with a median of $8.0 billion in 2024.
- Across the five-year window, Non-Current Assets rose 0.3% in 2022 and gained 10.68% in 2023, its largest moves.
- Year by year, Non-Current Assets stood at $7.4 billion in 2022, then increased by 7.06% to $7.9 billion in 2023, then gained by 3.41% to $8.2 billion in 2024, then gained by 6.12% to $8.7 billion in 2025, then retreated by 0.42% to $8.7 billion in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $8.7 billion in Q1 2026, $8.7 billion in Q4 2025, and $8.6 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 670.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.68 Bn |
| Dec 31, 2025 | 8.72 Bn |
| Sep 30, 2025 | 8.58 Bn |
| Jun 30, 2025 | 8.56 Bn |
| Mar 31, 2025 | 8.22 Bn |
| Dec 31, 2024 | 8.21 Bn |
| Sep 30, 2024 | 8.08 Bn |
| Jun 30, 2024 | 7.96 Bn |
| Mar 31, 2024 | 7.99 Bn |
| Dec 31, 2023 | 7.94 Bn |
| Sep 30, 2023 | 7.88 Bn |
| Jun 30, 2023 | 7.57 Bn |
| Mar 31, 2023 | 7.49 Bn |
| Dec 31, 2022 | 7.42 Bn |
| Sep 30, 2022 | 7.12 Bn |
| Jun 30, 2022 | 7.12 Bn |
| Mar 31, 2022 | 7.02 Bn |
| Dec 31, 2021 | 6.97 Bn |
| Sep 30, 2021 | 7.02 Bn |
| Jun 30, 2021 | 7.02 Bn |